nodes	percent_of_prediction	percent_of_DWPC	metapath
Niacin—SLC16A1—Methotrexate—bone cancer	0.369	0.917	CbGbCtD
Niacin—CYP2D6—Doxorubicin—bone cancer	0.0335	0.0831	CbGbCtD
Niacin—NNMT—Metapathway biotransformation—CYP4V2—bone cancer	0.0162	0.0808	CbGpPWpGaD
Niacin—QPRT—Nicotinate metabolism—PTGS2—bone cancer	0.014	0.0696	CbGpPWpGaD
Niacin—QPRT—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	0.00713	0.0355	CbGpPWpGaD
Niacin—Metyrapone—CYP3A4—bone cancer	0.00699	0.752	CrCbGaD
Niacin—SLC16A3—The citric acid (TCA) cycle and respiratory electron transport—NDUFA12—bone cancer	0.00632	0.0314	CbGpPWpGaD
Niacin—SLCO2B1—Farnesoid X Receptor  Pathway—CYP3A4—bone cancer	0.00563	0.028	CbGpPWpGaD
Niacin—NNMT—Phase II conjugation—GSTP1—bone cancer	0.00476	0.0237	CbGpPWpGaD
Niacin—HCAR2—G alpha (i) signalling events—RGS1—bone cancer	0.00471	0.0234	CbGpPWpGaD
Niacin—HCAR2—G alpha (i) signalling events—GRM4—bone cancer	0.00471	0.0234	CbGpPWpGaD
Niacin—HCAR3—G alpha (i) signalling events—RGS1—bone cancer	0.00446	0.0222	CbGpPWpGaD
Niacin—HCAR3—G alpha (i) signalling events—GRM4—bone cancer	0.00446	0.0222	CbGpPWpGaD
Niacin—SLC16A1—The citric acid (TCA) cycle and respiratory electron transport—NDUFA12—bone cancer	0.00341	0.017	CbGpPWpGaD
Niacin—NNMT—Biological oxidations—CYP3A4—bone cancer	0.00326	0.0162	CbGpPWpGaD
Niacin—NNMT—Metapathway biotransformation—CYP3A4—bone cancer	0.00321	0.016	CbGpPWpGaD
Niacin—SLC5A8—NRF2 pathway—GSTP1—bone cancer	0.00318	0.0158	CbGpPWpGaD
Niacin—SLC5A8—NRF2 pathway—TGFBR2—bone cancer	0.00318	0.0158	CbGpPWpGaD
Niacin—HCAR2—GPCR ligand binding—GRM4—bone cancer	0.00285	0.0142	CbGpPWpGaD
Niacin—NNMT—Biological oxidations—GSTP1—bone cancer	0.00279	0.0139	CbGpPWpGaD
Niacin—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00279	0.0138	CbGpPWpGaD
Niacin—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00277	0.0138	CbGpPWpGaD
Niacin—NNMT—Metapathway biotransformation—GSTP1—bone cancer	0.00275	0.0137	CbGpPWpGaD
Niacin—HCAR3—GPCR ligand binding—GRM4—bone cancer	0.0027	0.0134	CbGpPWpGaD
Niacin—QPRT—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—bone cancer	0.00268	0.0133	CbGpPWpGaD
Niacin—SLC5A8—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.0025	0.0124	CbGpPWpGaD
Niacin—HCAR2—GPCR ligand binding—GRM1—bone cancer	0.00247	0.0123	CbGpPWpGaD
Niacin—HCAR3—GPCR ligand binding—GRM1—bone cancer	0.00234	0.0117	CbGpPWpGaD
Niacin—Salicylic acid—PTGS2—bone cancer	0.00231	0.248	CrCbGaD
Niacin—SLC5A8—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00216	0.0107	CbGpPWpGaD
Niacin—QPRT—Metabolism—NDUFA12—bone cancer	0.0021	0.0104	CbGpPWpGaD
Niacin—NNMT—Metabolism—NDUFA12—bone cancer	0.00195	0.00971	CbGpPWpGaD
Niacin—HCAR2—GPCR ligand binding—SMO—bone cancer	0.00174	0.00866	CbGpPWpGaD
Niacin—QPRT—Metabolism—NT5C3A—bone cancer	0.00174	0.00865	CbGpPWpGaD
Niacin—HCAR3—GPCR ligand binding—SMO—bone cancer	0.00165	0.00821	CbGpPWpGaD
Niacin—NNMT—Metabolism—NT5C3A—bone cancer	0.00162	0.00804	CbGpPWpGaD
Niacin—HCAR2—GPCR downstream signaling—RGS1—bone cancer	0.00161	0.00801	CbGpPWpGaD
Niacin—HCAR2—GPCR downstream signaling—GRM4—bone cancer	0.00161	0.00801	CbGpPWpGaD
Niacin—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.0016	0.00795	CbGpPWpGaD
Niacin—HCAR3—GPCR downstream signaling—RGS1—bone cancer	0.00153	0.0076	CbGpPWpGaD
Niacin—HCAR3—GPCR downstream signaling—GRM4—bone cancer	0.00153	0.0076	CbGpPWpGaD
Niacin—HCAR2—Signaling by GPCR—RGS1—bone cancer	0.00146	0.00728	CbGpPWpGaD
Niacin—HCAR2—Signaling by GPCR—GRM4—bone cancer	0.00146	0.00728	CbGpPWpGaD
Niacin—HCAR2—GPCR downstream signaling—GRM1—bone cancer	0.0014	0.00695	CbGpPWpGaD
Niacin—HCAR3—Signaling by GPCR—RGS1—bone cancer	0.00139	0.0069	CbGpPWpGaD
Niacin—HCAR3—Signaling by GPCR—GRM4—bone cancer	0.00139	0.0069	CbGpPWpGaD
Niacin—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.00134	0.00665	CbGpPWpGaD
Niacin—HCAR3—GPCR downstream signaling—GRM1—bone cancer	0.00132	0.00659	CbGpPWpGaD
Niacin—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.00129	0.0064	CbGpPWpGaD
Niacin—HCAR2—Signaling by GPCR—GRM1—bone cancer	0.00127	0.00631	CbGpPWpGaD
Niacin—SLC16A3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00122	0.00606	CbGpPWpGaD
Niacin—HCAR3—Signaling by GPCR—GRM1—bone cancer	0.0012	0.00598	CbGpPWpGaD
Niacin—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.00119	0.00593	CbGpPWpGaD
Niacin—Arrhythmia—Cisplatin—bone cancer	0.00109	0.00283	CcSEcCtD
Niacin—Vaginal infection—Doxorubicin—bone cancer	0.00109	0.00283	CcSEcCtD
Niacin—Abnormal vision—Epirubicin—bone cancer	0.00109	0.00282	CcSEcCtD
Niacin—Alopecia—Cisplatin—bone cancer	0.00108	0.0028	CcSEcCtD
Niacin—Erythema—Cisplatin—bone cancer	0.00107	0.00276	CcSEcCtD
Niacin—Malnutrition—Cisplatin—bone cancer	0.00107	0.00276	CcSEcCtD
Niacin—Cramps of lower extremities—Doxorubicin—bone cancer	0.00106	0.00275	CcSEcCtD
Niacin—Oesophagitis—Doxorubicin—bone cancer	0.00106	0.00274	CcSEcCtD
Niacin—Rash maculo-papular—Doxorubicin—bone cancer	0.00105	0.00272	CcSEcCtD
Niacin—SLC16A3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00105	0.00523	CbGpPWpGaD
Niacin—Flatulence—Cisplatin—bone cancer	0.00105	0.00272	CcSEcCtD
Niacin—Diabetes mellitus—Epirubicin—bone cancer	0.00105	0.0027	CcSEcCtD
Niacin—Hepatic function abnormal—Epirubicin—bone cancer	0.00104	0.00269	CcSEcCtD
Niacin—Muscle spasms—Cisplatin—bone cancer	0.00103	0.00265	CcSEcCtD
Niacin—Hypertonia—Doxorubicin—bone cancer	0.00102	0.00263	CcSEcCtD
Niacin—Eczema—Epirubicin—bone cancer	0.00101	0.00262	CcSEcCtD
Niacin—Abnormal vision—Doxorubicin—bone cancer	0.00101	0.00261	CcSEcCtD
Niacin—Vision blurred—Cisplatin—bone cancer	0.001	0.0026	CcSEcCtD
Niacin—Diabetes mellitus—Doxorubicin—bone cancer	0.000967	0.0025	CcSEcCtD
Niacin—Hepatic function abnormal—Doxorubicin—bone cancer	0.000963	0.00249	CcSEcCtD
Niacin—Leukopenia—Cisplatin—bone cancer	0.000954	0.00247	CcSEcCtD
Niacin—SLC16A3—Metabolism—NDUFA12—bone cancer	0.000953	0.00474	CbGpPWpGaD
Niacin—Dermatitis bullous—Epirubicin—bone cancer	0.000951	0.00246	CcSEcCtD
Niacin—Eczema—Doxorubicin—bone cancer	0.000936	0.00242	CcSEcCtD
Niacin—QPRT—Disease—ENO2—bone cancer	0.00091	0.00453	CbGpPWpGaD
Niacin—Gastrointestinal haemorrhage—Epirubicin—bone cancer	0.000909	0.00235	CcSEcCtD
Niacin—Myalgia—Cisplatin—bone cancer	0.000908	0.00235	CcSEcCtD
Niacin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000901	0.00233	CcSEcCtD
Niacin—HCAR2—GPCR downstream signaling—GNA11—bone cancer	0.0009	0.00448	CbGpPWpGaD
Niacin—Liver function test abnormal—Methotrexate—bone cancer	0.000897	0.00232	CcSEcCtD
Niacin—Migraine—Epirubicin—bone cancer	0.000895	0.00231	CcSEcCtD
Niacin—HCAR2—Signaling by GPCR—SMO—bone cancer	0.000894	0.00445	CbGpPWpGaD
Niacin—Dermatitis bullous—Doxorubicin—bone cancer	0.00088	0.00228	CcSEcCtD
Niacin—Face oedema—Epirubicin—bone cancer	0.000878	0.00227	CcSEcCtD
Niacin—Oedema—Cisplatin—bone cancer	0.00087	0.00225	CcSEcCtD
Niacin—Anaphylactic shock—Cisplatin—bone cancer	0.00087	0.00225	CcSEcCtD
Niacin—HCAR2—Signaling Pathways—GRM4—bone cancer	0.000865	0.0043	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—RGS1—bone cancer	0.000865	0.0043	CbGpPWpGaD
Niacin—HCAR3—GPCR downstream signaling—GNA11—bone cancer	0.000854	0.00424	CbGpPWpGaD
Niacin—Tachycardia—Cisplatin—bone cancer	0.000849	0.0022	CcSEcCtD
Niacin—HCAR3—Signaling by GPCR—SMO—bone cancer	0.000848	0.00421	CbGpPWpGaD
Niacin—Skin disorder—Cisplatin—bone cancer	0.000845	0.00218	CcSEcCtD
Niacin—QPRT—Disease—DHFR—bone cancer	0.000844	0.0042	CbGpPWpGaD
Niacin—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	0.000841	0.00217	CcSEcCtD
Niacin—Hyperhidrosis—Cisplatin—bone cancer	0.000841	0.00217	CcSEcCtD
Niacin—Liver function test abnormal—Epirubicin—bone cancer	0.000839	0.00217	CcSEcCtD
Niacin—Dry skin—Epirubicin—bone cancer	0.000833	0.00215	CcSEcCtD
Niacin—Orthostatic hypotension—Epirubicin—bone cancer	0.00083	0.00215	CcSEcCtD
Niacin—Anorexia—Cisplatin—bone cancer	0.000829	0.00214	CcSEcCtD
Niacin—Migraine—Doxorubicin—bone cancer	0.000828	0.00214	CcSEcCtD
Niacin—HCAR3—Signaling Pathways—RGS1—bone cancer	0.00082	0.00408	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—GRM4—bone cancer	0.00082	0.00408	CbGpPWpGaD
Niacin—HCAR2—Signaling by GPCR—GNA11—bone cancer	0.000818	0.00407	CbGpPWpGaD
Niacin—HCAR2—GPCR downstream signaling—IL3—bone cancer	0.000816	0.00406	CbGpPWpGaD
Niacin—Hypotension—Cisplatin—bone cancer	0.000813	0.0021	CcSEcCtD
Niacin—Face oedema—Doxorubicin—bone cancer	0.000812	0.0021	CcSEcCtD
Niacin—SLC16A3—Hemostasis—SPARC—bone cancer	0.000809	0.00402	CbGpPWpGaD
Niacin—Muscular weakness—Epirubicin—bone cancer	0.000802	0.00207	CcSEcCtD
Niacin—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000793	0.00205	CcSEcCtD
Niacin—Abdominal distension—Epirubicin—bone cancer	0.000791	0.00205	CcSEcCtD
Niacin—SLC16A3—Metabolism—NT5C3A—bone cancer	0.00079	0.00393	CbGpPWpGaD
Niacin—Influenza—Epirubicin—bone cancer	0.000786	0.00203	CcSEcCtD
Niacin—Dysphagia—Epirubicin—bone cancer	0.000786	0.00203	CcSEcCtD
Niacin—Paraesthesia—Cisplatin—bone cancer	0.000781	0.00202	CcSEcCtD
Niacin—Liver function test abnormal—Doxorubicin—bone cancer	0.000777	0.00201	CcSEcCtD
Niacin—Dyspnoea—Cisplatin—bone cancer	0.000776	0.00201	CcSEcCtD
Niacin—HCAR3—Signaling by GPCR—GNA11—bone cancer	0.000775	0.00385	CbGpPWpGaD
Niacin—HCAR3—GPCR downstream signaling—IL3—bone cancer	0.000774	0.00385	CbGpPWpGaD
Niacin—Erectile dysfunction—Methotrexate—bone cancer	0.000773	0.002	CcSEcCtD
Niacin—Dry skin—Doxorubicin—bone cancer	0.000771	0.00199	CcSEcCtD
Niacin—Orthostatic hypotension—Doxorubicin—bone cancer	0.000768	0.00199	CcSEcCtD
Niacin—Angina pectoris—Epirubicin—bone cancer	0.000765	0.00198	CcSEcCtD
Niacin—QPRT—Metabolism—ENO2—bone cancer	0.000762	0.00379	CbGpPWpGaD
Niacin—Decreased appetite—Cisplatin—bone cancer	0.000756	0.00196	CcSEcCtD
Niacin—Bronchitis—Epirubicin—bone cancer	0.000756	0.00195	CcSEcCtD
Niacin—Gastrointestinal disorder—Cisplatin—bone cancer	0.000751	0.00194	CcSEcCtD
Niacin—HCAR2—Signaling Pathways—GRM1—bone cancer	0.00075	0.00373	CbGpPWpGaD
Niacin—Pain—Cisplatin—bone cancer	0.000744	0.00192	CcSEcCtD
Niacin—Muscular weakness—Doxorubicin—bone cancer	0.000742	0.00192	CcSEcCtD
Niacin—HCAR2—Signaling by GPCR—IL3—bone cancer	0.000741	0.00369	CbGpPWpGaD
Niacin—SLCO2B1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000741	0.00369	CbGpPWpGaD
Niacin—SLC16A3—Hemostasis—GNA11—bone cancer	0.00074	0.00368	CbGpPWpGaD
Niacin—Abdominal distension—Doxorubicin—bone cancer	0.000732	0.00189	CcSEcCtD
Niacin—Stomatitis—Methotrexate—bone cancer	0.00073	0.00189	CcSEcCtD
Niacin—Dysphagia—Doxorubicin—bone cancer	0.000727	0.00188	CcSEcCtD
Niacin—Influenza—Doxorubicin—bone cancer	0.000727	0.00188	CcSEcCtD
Niacin—Sweating—Methotrexate—bone cancer	0.000718	0.00186	CcSEcCtD
Niacin—HCAR3—Signaling Pathways—GRM1—bone cancer	0.000711	0.00353	CbGpPWpGaD
Niacin—NNMT—Metabolism—ENO2—bone cancer	0.000709	0.00352	CbGpPWpGaD
Niacin—Angina pectoris—Doxorubicin—bone cancer	0.000708	0.00183	CcSEcCtD
Niacin—QPRT—Metabolism—DHFR—bone cancer	0.000707	0.00352	CbGpPWpGaD
Niacin—HCAR3—Signaling by GPCR—IL3—bone cancer	0.000703	0.00349	CbGpPWpGaD
Niacin—Bronchitis—Doxorubicin—bone cancer	0.000699	0.00181	CcSEcCtD
Niacin—Body temperature increased—Cisplatin—bone cancer	0.000688	0.00178	CcSEcCtD
Niacin—Jaundice—Epirubicin—bone cancer	0.000683	0.00177	CcSEcCtD
Niacin—Stomatitis—Epirubicin—bone cancer	0.000683	0.00177	CcSEcCtD
Niacin—Haemoglobin—Methotrexate—bone cancer	0.000675	0.00175	CcSEcCtD
Niacin—Haemorrhage—Methotrexate—bone cancer	0.000672	0.00174	CcSEcCtD
Niacin—Hepatitis—Methotrexate—bone cancer	0.000672	0.00174	CcSEcCtD
Niacin—Sweating—Epirubicin—bone cancer	0.000672	0.00174	CcSEcCtD
Niacin—SLC16A3—Hemostasis—IL3—bone cancer	0.000671	0.00334	CbGpPWpGaD
Niacin—QPRT—Metabolism—GNA11—bone cancer	0.000661	0.00329	CbGpPWpGaD
Niacin—SLC16A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000659	0.00327	CbGpPWpGaD
Niacin—NNMT—Metabolism—DHFR—bone cancer	0.000657	0.00327	CbGpPWpGaD
Niacin—Visual impairment—Methotrexate—bone cancer	0.000648	0.00167	CcSEcCtD
Niacin—Hypersensitivity—Cisplatin—bone cancer	0.000641	0.00166	CcSEcCtD
Niacin—SLCO2B1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00064	0.00318	CbGpPWpGaD
Niacin—Haemoglobin—Epirubicin—bone cancer	0.000632	0.00163	CcSEcCtD
Niacin—Stomatitis—Doxorubicin—bone cancer	0.000632	0.00163	CcSEcCtD
Niacin—Jaundice—Doxorubicin—bone cancer	0.000632	0.00163	CcSEcCtD
Niacin—Rhinitis—Epirubicin—bone cancer	0.000631	0.00163	CcSEcCtD
Niacin—Haemorrhage—Epirubicin—bone cancer	0.000629	0.00163	CcSEcCtD
Niacin—Hepatitis—Epirubicin—bone cancer	0.000629	0.00163	CcSEcCtD
Niacin—Eye disorder—Methotrexate—bone cancer	0.000628	0.00162	CcSEcCtD
Niacin—Tinnitus—Methotrexate—bone cancer	0.000627	0.00162	CcSEcCtD
Niacin—Hypoaesthesia—Epirubicin—bone cancer	0.000626	0.00162	CcSEcCtD
Niacin—Asthenia—Cisplatin—bone cancer	0.000624	0.00161	CcSEcCtD
Niacin—Sweating—Doxorubicin—bone cancer	0.000621	0.00161	CcSEcCtD
Niacin—Oedema peripheral—Epirubicin—bone cancer	0.00062	0.0016	CcSEcCtD
Niacin—NNMT—Metabolism—GNA11—bone cancer	0.000614	0.00306	CbGpPWpGaD
Niacin—QPRT—Disease—TGFBR2—bone cancer	0.000612	0.00304	CbGpPWpGaD
Niacin—Angiopathy—Methotrexate—bone cancer	0.00061	0.00158	CcSEcCtD
Niacin—Visual impairment—Epirubicin—bone cancer	0.000606	0.00157	CcSEcCtD
Niacin—Chills—Methotrexate—bone cancer	0.000603	0.00156	CcSEcCtD
Niacin—QPRT—Metabolism—CYP3A4—bone cancer	0.000599	0.00298	CbGpPWpGaD
Niacin—Diarrhoea—Cisplatin—bone cancer	0.000595	0.00154	CcSEcCtD
Niacin—Alopecia—Methotrexate—bone cancer	0.000594	0.00154	CcSEcCtD
Niacin—Eye disorder—Epirubicin—bone cancer	0.000588	0.00152	CcSEcCtD
Niacin—Tinnitus—Epirubicin—bone cancer	0.000586	0.00152	CcSEcCtD
Niacin—Malnutrition—Methotrexate—bone cancer	0.000585	0.00151	CcSEcCtD
Niacin—Erythema—Methotrexate—bone cancer	0.000585	0.00151	CcSEcCtD
Niacin—Haemoglobin—Doxorubicin—bone cancer	0.000585	0.00151	CcSEcCtD
Niacin—Flushing—Epirubicin—bone cancer	0.000584	0.00151	CcSEcCtD
Niacin—Rhinitis—Doxorubicin—bone cancer	0.000583	0.00151	CcSEcCtD
Niacin—Haemorrhage—Doxorubicin—bone cancer	0.000582	0.0015	CcSEcCtD
Niacin—Hepatitis—Doxorubicin—bone cancer	0.000582	0.0015	CcSEcCtD
Niacin—Hypoaesthesia—Doxorubicin—bone cancer	0.000579	0.0015	CcSEcCtD
Niacin—Oedema peripheral—Doxorubicin—bone cancer	0.000573	0.00148	CcSEcCtD
Niacin—Angiopathy—Epirubicin—bone cancer	0.000571	0.00148	CcSEcCtD
Niacin—SLC16A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000568	0.00283	CbGpPWpGaD
Niacin—SLC22A5—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000566	0.00282	CbGpPWpGaD
Niacin—Chills—Epirubicin—bone cancer	0.000564	0.00146	CcSEcCtD
Niacin—Arrhythmia—Epirubicin—bone cancer	0.000562	0.00145	CcSEcCtD
Niacin—Visual impairment—Doxorubicin—bone cancer	0.000561	0.00145	CcSEcCtD
Niacin—NNMT—Metabolism—CYP3A4—bone cancer	0.000557	0.00277	CbGpPWpGaD
Niacin—Alopecia—Epirubicin—bone cancer	0.000556	0.00144	CcSEcCtD
Niacin—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000556	0.00276	CbGpPWpGaD
Niacin—Vomiting—Cisplatin—bone cancer	0.000553	0.00143	CcSEcCtD
Niacin—Vision blurred—Methotrexate—bone cancer	0.000551	0.00143	CcSEcCtD
Niacin—Rash—Cisplatin—bone cancer	0.000549	0.00142	CcSEcCtD
Niacin—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000548	0.00273	CbGpPWpGaD
Niacin—Dermatitis—Cisplatin—bone cancer	0.000548	0.00142	CcSEcCtD
Niacin—Erythema—Epirubicin—bone cancer	0.000548	0.00142	CcSEcCtD
Niacin—Malnutrition—Epirubicin—bone cancer	0.000548	0.00142	CcSEcCtD
Niacin—Eye disorder—Doxorubicin—bone cancer	0.000544	0.00141	CcSEcCtD
Niacin—Tinnitus—Doxorubicin—bone cancer	0.000543	0.0014	CcSEcCtD
Niacin—Flushing—Doxorubicin—bone cancer	0.00054	0.0014	CcSEcCtD
Niacin—Flatulence—Epirubicin—bone cancer	0.00054	0.00139	CcSEcCtD
Niacin—Tension—Epirubicin—bone cancer	0.000537	0.00139	CcSEcCtD
Niacin—Nervousness—Epirubicin—bone cancer	0.000532	0.00137	CcSEcCtD
Niacin—HCAR2—Signaling Pathways—SMO—bone cancer	0.000528	0.00263	CbGpPWpGaD
Niacin—Angiopathy—Doxorubicin—bone cancer	0.000528	0.00136	CcSEcCtD
Niacin—Muscle spasms—Epirubicin—bone cancer	0.000526	0.00136	CcSEcCtD
Niacin—Vertigo—Methotrexate—bone cancer	0.000526	0.00136	CcSEcCtD
Niacin—Leukopenia—Methotrexate—bone cancer	0.000524	0.00135	CcSEcCtD
Niacin—Chills—Doxorubicin—bone cancer	0.000522	0.00135	CcSEcCtD
Niacin—Arrhythmia—Doxorubicin—bone cancer	0.00052	0.00134	CcSEcCtD
Niacin—Nausea—Cisplatin—bone cancer	0.000517	0.00134	CcSEcCtD
Niacin—Vision blurred—Epirubicin—bone cancer	0.000516	0.00133	CcSEcCtD
Niacin—SLC16A1—Metabolism—NDUFA12—bone cancer	0.000515	0.00256	CbGpPWpGaD
Niacin—Alopecia—Doxorubicin—bone cancer	0.000514	0.00133	CcSEcCtD
Niacin—QPRT—Metabolism—GSTP1—bone cancer	0.000512	0.00255	CbGpPWpGaD
Niacin—Cough—Methotrexate—bone cancer	0.000511	0.00132	CcSEcCtD
Niacin—Erythema—Doxorubicin—bone cancer	0.000507	0.00131	CcSEcCtD
Niacin—Malnutrition—Doxorubicin—bone cancer	0.000507	0.00131	CcSEcCtD
Niacin—HCAR3—Signaling Pathways—SMO—bone cancer	0.000501	0.00249	CbGpPWpGaD
Niacin—Flatulence—Doxorubicin—bone cancer	0.000499	0.00129	CcSEcCtD
Niacin—Arthralgia—Methotrexate—bone cancer	0.000498	0.00129	CcSEcCtD
Niacin—Myalgia—Methotrexate—bone cancer	0.000498	0.00129	CcSEcCtD
Niacin—Tension—Doxorubicin—bone cancer	0.000497	0.00129	CcSEcCtD
Niacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000495	0.00128	CcSEcCtD
Niacin—Nervousness—Doxorubicin—bone cancer	0.000492	0.00127	CcSEcCtD
Niacin—Vertigo—Epirubicin—bone cancer	0.000492	0.00127	CcSEcCtD
Niacin—Syncope—Epirubicin—bone cancer	0.000491	0.00127	CcSEcCtD
Niacin—Leukopenia—Epirubicin—bone cancer	0.00049	0.00127	CcSEcCtD
Niacin—SLC22A5—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000489	0.00243	CbGpPWpGaD
Niacin—Muscle spasms—Doxorubicin—bone cancer	0.000487	0.00126	CcSEcCtD
Niacin—Palpitations—Epirubicin—bone cancer	0.000484	0.00125	CcSEcCtD
Niacin—HCAR2—Signaling Pathways—GNA11—bone cancer	0.000483	0.0024	CbGpPWpGaD
Niacin—Loss of consciousness—Epirubicin—bone cancer	0.000481	0.00124	CcSEcCtD
Niacin—Cough—Epirubicin—bone cancer	0.000478	0.00124	CcSEcCtD
Niacin—Anaphylactic shock—Methotrexate—bone cancer	0.000477	0.00123	CcSEcCtD
Niacin—Vision blurred—Doxorubicin—bone cancer	0.000477	0.00123	CcSEcCtD
Niacin—NNMT—Metabolism—GSTP1—bone cancer	0.000476	0.00237	CbGpPWpGaD
Niacin—Myalgia—Epirubicin—bone cancer	0.000466	0.00121	CcSEcCtD
Niacin—Arthralgia—Epirubicin—bone cancer	0.000466	0.00121	CcSEcCtD
Niacin—Skin disorder—Methotrexate—bone cancer	0.000464	0.0012	CcSEcCtD
Niacin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000463	0.0012	CcSEcCtD
Niacin—Hyperhidrosis—Methotrexate—bone cancer	0.000462	0.00119	CcSEcCtD
Niacin—HCAR3—Signaling Pathways—GNA11—bone cancer	0.000458	0.00228	CbGpPWpGaD
Niacin—Dry mouth—Epirubicin—bone cancer	0.000456	0.00118	CcSEcCtD
Niacin—Vertigo—Doxorubicin—bone cancer	0.000455	0.00118	CcSEcCtD
Niacin—Anorexia—Methotrexate—bone cancer	0.000455	0.00118	CcSEcCtD
Niacin—Syncope—Doxorubicin—bone cancer	0.000454	0.00117	CcSEcCtD
Niacin—Leukopenia—Doxorubicin—bone cancer	0.000453	0.00117	CcSEcCtD
Niacin—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00045	0.00224	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—ATF1—bone cancer	0.000449	0.00223	CbGpPWpGaD
Niacin—Palpitations—Doxorubicin—bone cancer	0.000448	0.00116	CcSEcCtD
Niacin—Anaphylactic shock—Epirubicin—bone cancer	0.000447	0.00116	CcSEcCtD
Niacin—Oedema—Epirubicin—bone cancer	0.000447	0.00116	CcSEcCtD
Niacin—Hypotension—Methotrexate—bone cancer	0.000446	0.00115	CcSEcCtD
Niacin—Loss of consciousness—Doxorubicin—bone cancer	0.000445	0.00115	CcSEcCtD
Niacin—Cough—Doxorubicin—bone cancer	0.000442	0.00114	CcSEcCtD
Niacin—SLC16A3—Hemostasis—PLAU—bone cancer	0.00044	0.00219	CbGpPWpGaD
Niacin—Shock—Epirubicin—bone cancer	0.00044	0.00114	CcSEcCtD
Niacin—HCAR2—Signaling Pathways—IL3—bone cancer	0.000438	0.00218	CbGpPWpGaD
Niacin—SLC16A1—Hemostasis—SPARC—bone cancer	0.000437	0.00217	CbGpPWpGaD
Niacin—Tachycardia—Epirubicin—bone cancer	0.000436	0.00113	CcSEcCtD
Niacin—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000435	0.00112	CcSEcCtD
Niacin—Skin disorder—Epirubicin—bone cancer	0.000434	0.00112	CcSEcCtD
Niacin—Hyperhidrosis—Epirubicin—bone cancer	0.000432	0.00112	CcSEcCtD
Niacin—Insomnia—Methotrexate—bone cancer	0.000432	0.00112	CcSEcCtD
Niacin—Arthralgia—Doxorubicin—bone cancer	0.000431	0.00111	CcSEcCtD
Niacin—Myalgia—Doxorubicin—bone cancer	0.000431	0.00111	CcSEcCtD
Niacin—Paraesthesia—Methotrexate—bone cancer	0.000429	0.00111	CcSEcCtD
Niacin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000428	0.00111	CcSEcCtD
Niacin—SLC16A1—Metabolism—NT5C3A—bone cancer	0.000427	0.00212	CbGpPWpGaD
Niacin—Anorexia—Epirubicin—bone cancer	0.000426	0.0011	CcSEcCtD
Niacin—Dyspnoea—Methotrexate—bone cancer	0.000426	0.0011	CcSEcCtD
Niacin—HCAR3—Signaling Pathways—ATF1—bone cancer	0.000426	0.00212	CbGpPWpGaD
Niacin—Somnolence—Methotrexate—bone cancer	0.000424	0.0011	CcSEcCtD
Niacin—Dry mouth—Doxorubicin—bone cancer	0.000422	0.00109	CcSEcCtD
Niacin—Dyspepsia—Methotrexate—bone cancer	0.00042	0.00109	CcSEcCtD
Niacin—Hypotension—Epirubicin—bone cancer	0.000418	0.00108	CcSEcCtD
Niacin—QPRT—Disease—KIT—bone cancer	0.000418	0.00208	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—IL3—bone cancer	0.000415	0.00206	CbGpPWpGaD
Niacin—Decreased appetite—Methotrexate—bone cancer	0.000415	0.00107	CcSEcCtD
Niacin—Oedema—Doxorubicin—bone cancer	0.000413	0.00107	CcSEcCtD
Niacin—Anaphylactic shock—Doxorubicin—bone cancer	0.000413	0.00107	CcSEcCtD
Niacin—Gastrointestinal disorder—Methotrexate—bone cancer	0.000412	0.00107	CcSEcCtD
Niacin—Pain—Methotrexate—bone cancer	0.000408	0.00106	CcSEcCtD
Niacin—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000407	0.00105	CcSEcCtD
Niacin—Shock—Doxorubicin—bone cancer	0.000407	0.00105	CcSEcCtD
Niacin—Insomnia—Epirubicin—bone cancer	0.000404	0.00104	CcSEcCtD
Niacin—Tachycardia—Doxorubicin—bone cancer	0.000404	0.00104	CcSEcCtD
Niacin—Skin disorder—Doxorubicin—bone cancer	0.000402	0.00104	CcSEcCtD
Niacin—Paraesthesia—Epirubicin—bone cancer	0.000401	0.00104	CcSEcCtD
Niacin—Hyperhidrosis—Doxorubicin—bone cancer	0.0004	0.00103	CcSEcCtD
Niacin—SLC16A1—Hemostasis—GNA11—bone cancer	0.0004	0.00199	CbGpPWpGaD
Niacin—Dyspnoea—Epirubicin—bone cancer	0.000398	0.00103	CcSEcCtD
Niacin—Somnolence—Epirubicin—bone cancer	0.000397	0.00103	CcSEcCtD
Niacin—Anorexia—Doxorubicin—bone cancer	0.000394	0.00102	CcSEcCtD
Niacin—Dyspepsia—Epirubicin—bone cancer	0.000393	0.00102	CcSEcCtD
Niacin—QPRT—Disease—BRAF—bone cancer	0.000392	0.00195	CbGpPWpGaD
Niacin—Gastrointestinal pain—Methotrexate—bone cancer	0.00039	0.00101	CcSEcCtD
Niacin—Decreased appetite—Epirubicin—bone cancer	0.000388	0.001	CcSEcCtD
Niacin—Hypotension—Doxorubicin—bone cancer	0.000386	0.000999	CcSEcCtD
Niacin—Gastrointestinal disorder—Epirubicin—bone cancer	0.000386	0.000997	CcSEcCtD
Niacin—Pain—Epirubicin—bone cancer	0.000382	0.000988	CcSEcCtD
Niacin—Urticaria—Methotrexate—bone cancer	0.000379	0.000981	CcSEcCtD
Niacin—Abdominal pain—Methotrexate—bone cancer	0.000377	0.000976	CcSEcCtD
Niacin—Body temperature increased—Methotrexate—bone cancer	0.000377	0.000976	CcSEcCtD
Niacin—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000377	0.000974	CcSEcCtD
Niacin—HCAR2—Signaling Pathways—TGFBR2—bone cancer	0.000375	0.00186	CbGpPWpGaD
Niacin—Insomnia—Doxorubicin—bone cancer	0.000374	0.000967	CcSEcCtD
Niacin—Paraesthesia—Doxorubicin—bone cancer	0.000371	0.00096	CcSEcCtD
Niacin—Dyspnoea—Doxorubicin—bone cancer	0.000369	0.000953	CcSEcCtD
Niacin—Somnolence—Doxorubicin—bone cancer	0.000368	0.00095	CcSEcCtD
Niacin—Gastrointestinal pain—Epirubicin—bone cancer	0.000365	0.000945	CcSEcCtD
Niacin—Dyspepsia—Doxorubicin—bone cancer	0.000364	0.000941	CcSEcCtD
Niacin—SLC16A1—Hemostasis—IL3—bone cancer	0.000362	0.0018	CbGpPWpGaD
Niacin—Decreased appetite—Doxorubicin—bone cancer	0.000359	0.000929	CcSEcCtD
Niacin—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000357	0.000923	CcSEcCtD
Niacin—HCAR3—Signaling Pathways—TGFBR2—bone cancer	0.000355	0.00177	CbGpPWpGaD
Niacin—Urticaria—Epirubicin—bone cancer	0.000355	0.000918	CcSEcCtD
Niacin—Pain—Doxorubicin—bone cancer	0.000354	0.000914	CcSEcCtD
Niacin—Body temperature increased—Epirubicin—bone cancer	0.000353	0.000913	CcSEcCtD
Niacin—Abdominal pain—Epirubicin—bone cancer	0.000353	0.000913	CcSEcCtD
Niacin—HCAR2—Signaling Pathways—IGF1R—bone cancer	0.000352	0.00175	CbGpPWpGaD
Niacin—Hypersensitivity—Methotrexate—bone cancer	0.000352	0.000909	CcSEcCtD
Niacin—SLC16A3—Metabolism—ENO2—bone cancer	0.000346	0.00172	CbGpPWpGaD
Niacin—Asthenia—Methotrexate—bone cancer	0.000343	0.000886	CcSEcCtD
Niacin—Gastrointestinal pain—Doxorubicin—bone cancer	0.000338	0.000874	CcSEcCtD
Niacin—Pruritus—Methotrexate—bone cancer	0.000338	0.000873	CcSEcCtD
Niacin—HCAR3—Signaling Pathways—IGF1R—bone cancer	0.000334	0.00166	CbGpPWpGaD
Niacin—Hypersensitivity—Epirubicin—bone cancer	0.000329	0.000851	CcSEcCtD
Niacin—QPRT—Disease—MDM2—bone cancer	0.000329	0.00164	CbGpPWpGaD
Niacin—Urticaria—Doxorubicin—bone cancer	0.000328	0.000849	CcSEcCtD
Niacin—Body temperature increased—Doxorubicin—bone cancer	0.000327	0.000845	CcSEcCtD
Niacin—Abdominal pain—Doxorubicin—bone cancer	0.000327	0.000845	CcSEcCtD
Niacin—Diarrhoea—Methotrexate—bone cancer	0.000327	0.000845	CcSEcCtD
Niacin—SLC16A3—Metabolism—DHFR—bone cancer	0.000321	0.0016	CbGpPWpGaD
Niacin—Asthenia—Epirubicin—bone cancer	0.000321	0.000829	CcSEcCtD
Niacin—QPRT—Disease—PTGS2—bone cancer	0.000317	0.00158	CbGpPWpGaD
Niacin—Pruritus—Epirubicin—bone cancer	0.000316	0.000817	CcSEcCtD
Niacin—Dizziness—Methotrexate—bone cancer	0.000316	0.000816	CcSEcCtD
Niacin—Diarrhoea—Epirubicin—bone cancer	0.000306	0.00079	CcSEcCtD
Niacin—Hypersensitivity—Doxorubicin—bone cancer	0.000305	0.000787	CcSEcCtD
Niacin—Vomiting—Methotrexate—bone cancer	0.000304	0.000785	CcSEcCtD
Niacin—Rash—Methotrexate—bone cancer	0.000301	0.000778	CcSEcCtD
Niacin—Dermatitis—Methotrexate—bone cancer	0.000301	0.000778	CcSEcCtD
Niacin—SLC16A3—Metabolism—GNA11—bone cancer	0.0003	0.00149	CbGpPWpGaD
Niacin—Headache—Methotrexate—bone cancer	0.000299	0.000773	CcSEcCtD
Niacin—Asthenia—Doxorubicin—bone cancer	0.000297	0.000767	CcSEcCtD
Niacin—Dizziness—Epirubicin—bone cancer	0.000295	0.000764	CcSEcCtD
Niacin—Pruritus—Doxorubicin—bone cancer	0.000293	0.000756	CcSEcCtD
Niacin—Vomiting—Epirubicin—bone cancer	0.000284	0.000734	CcSEcCtD
Niacin—Nausea—Methotrexate—bone cancer	0.000284	0.000733	CcSEcCtD
Niacin—Diarrhoea—Doxorubicin—bone cancer	0.000283	0.000731	CcSEcCtD
Niacin—Rash—Epirubicin—bone cancer	0.000282	0.000728	CcSEcCtD
Niacin—Dermatitis—Epirubicin—bone cancer	0.000281	0.000728	CcSEcCtD
Niacin—Headache—Epirubicin—bone cancer	0.00028	0.000724	CcSEcCtD
Niacin—Dizziness—Doxorubicin—bone cancer	0.000273	0.000707	CcSEcCtD
Niacin—SLC16A3—Metabolism—CYP3A4—bone cancer	0.000272	0.00135	CbGpPWpGaD
Niacin—QPRT—Metabolism—PTGS2—bone cancer	0.000265	0.00132	CbGpPWpGaD
Niacin—Nausea—Epirubicin—bone cancer	0.000265	0.000686	CcSEcCtD
Niacin—Vomiting—Doxorubicin—bone cancer	0.000263	0.00068	CcSEcCtD
Niacin—Rash—Doxorubicin—bone cancer	0.000261	0.000674	CcSEcCtD
Niacin—Dermatitis—Doxorubicin—bone cancer	0.00026	0.000673	CcSEcCtD
Niacin—Headache—Doxorubicin—bone cancer	0.000259	0.00067	CcSEcCtD
Niacin—HCAR2—Signaling Pathways—KIT—bone cancer	0.000256	0.00127	CbGpPWpGaD
Niacin—NNMT—Metabolism—PTGS2—bone cancer	0.000247	0.00123	CbGpPWpGaD
Niacin—Nausea—Doxorubicin—bone cancer	0.000246	0.000635	CcSEcCtD
Niacin—HCAR3—Signaling Pathways—KIT—bone cancer	0.000242	0.0012	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—BRAF—bone cancer	0.00024	0.00119	CbGpPWpGaD
Niacin—CYP2D6—Biological oxidations—CYP3A4—bone cancer	0.000239	0.00119	CbGpPWpGaD
Niacin—SLC16A1—Hemostasis—PLAU—bone cancer	0.000238	0.00118	CbGpPWpGaD
Niacin—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	0.000236	0.00117	CbGpPWpGaD
Niacin—HCAR2—Signaling by GPCR—EGFR—bone cancer	0.000233	0.00116	CbGpPWpGaD
Niacin—SLC16A3—Metabolism—GSTP1—bone cancer	0.000233	0.00116	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—BRAF—bone cancer	0.000228	0.00113	CbGpPWpGaD
Niacin—QPRT—Disease—EGFR—bone cancer	0.000225	0.00112	CbGpPWpGaD
Niacin—HCAR3—Signaling by GPCR—EGFR—bone cancer	0.000221	0.0011	CbGpPWpGaD
Niacin—CYP2D6—Biological oxidations—GSTP1—bone cancer	0.000205	0.00102	CbGpPWpGaD
Niacin—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	0.000202	0.001	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—MDM2—bone cancer	0.000201	0.001	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—MDM2—bone cancer	0.000191	0.000949	CbGpPWpGaD
Niacin—SLC16A1—Metabolism—ENO2—bone cancer	0.000187	0.000929	CbGpPWpGaD
Niacin—SLC16A3—Hemostasis—TP53—bone cancer	0.000177	0.00088	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—JUN—bone cancer	0.000175	0.00087	CbGpPWpGaD
Niacin—SLC16A1—Metabolism—DHFR—bone cancer	0.000173	0.000862	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—MMP9—bone cancer	0.00017	0.000846	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—JUN—bone cancer	0.000166	0.000825	CbGpPWpGaD
Niacin—SLC16A1—Metabolism—GNA11—bone cancer	0.000162	0.000806	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—MMP9—bone cancer	0.000161	0.000802	CbGpPWpGaD
Niacin—SLC16A1—Metabolism—CYP3A4—bone cancer	0.000147	0.00073	CbGpPWpGaD
Niacin—CYP2D6—Metabolism—NDUFA12—bone cancer	0.000143	0.000713	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—EGFR—bone cancer	0.000138	0.000684	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—EGFR—bone cancer	0.00013	0.000648	CbGpPWpGaD
Niacin—SLC16A1—Metabolism—GSTP1—bone cancer	0.000126	0.000625	CbGpPWpGaD
Niacin—SLC16A3—Metabolism—PTGS2—bone cancer	0.000121	0.000599	CbGpPWpGaD
Niacin—CYP2D6—Metabolism—NT5C3A—bone cancer	0.000119	0.000591	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—TP53—bone cancer	0.000115	0.000574	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—TP53—bone cancer	0.000109	0.000544	CbGpPWpGaD
Niacin—SLC16A1—Hemostasis—TP53—bone cancer	9.55e-05	0.000475	CbGpPWpGaD
Niacin—SLC16A1—Metabolism—PTGS2—bone cancer	6.51e-05	0.000324	CbGpPWpGaD
Niacin—CYP2D6—Metabolism—ENO2—bone cancer	5.21e-05	0.000259	CbGpPWpGaD
Niacin—CYP2D6—Metabolism—DHFR—bone cancer	4.83e-05	0.00024	CbGpPWpGaD
Niacin—CYP2D6—Metabolism—GNA11—bone cancer	4.51e-05	0.000224	CbGpPWpGaD
Niacin—CYP2D6—Metabolism—CYP3A4—bone cancer	4.09e-05	0.000203	CbGpPWpGaD
Niacin—CYP2D6—Metabolism—GSTP1—bone cancer	3.5e-05	0.000174	CbGpPWpGaD
Niacin—CYP2D6—Metabolism—PTGS2—bone cancer	1.81e-05	9.02e-05	CbGpPWpGaD
